Gyre Therapeutics, Inc.
GYRE
$8.52
-$0.29-3.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 12.09M | -88.82M | -85.97M | -87.65M | -92.93M |
| Total Depreciation and Amortization | 1.59M | 1.43M | 1.17M | 1.25M | 1.11M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.54M | 98.19M | 100.37M | 101.03M | 100.99M |
| Change in Net Operating Assets | -22.86M | -8.31M | -7.24M | 3.72M | 16.72M |
| Cash from Operations | -3.64M | 2.48M | 8.33M | 18.36M | 25.89M |
| Capital Expenditure | -2.32M | -4.70M | -5.99M | -7.01M | -8.52M |
| Sale of Property, Plant, and Equipment | 401.00K | 430.00K | 798.00K | 714.00K | 664.00K |
| Cash Acquisitions | -- | 5.46M | 5.46M | 5.46M | 5.46M |
| Divestitures | -- | -566.00K | -566.00K | -566.00K | -566.00K |
| Other Investing Activities | -17.97M | -17.16M | -19.26M | -17.94M | -16.80M |
| Cash from Investing | -19.88M | -16.54M | -19.55M | -19.33M | -19.76M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.64M | 1.31M | 933.00K | 658.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 2.50M | 2.50M | 2.50M | 2.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -536.00K | -169.00K | -119.00K | -- | -- |
| Cash from Financing | 2.10M | 3.64M | 3.31M | 3.16M | 2.50M |
| Foreign Exchange rate Adjustments | -273.00K | 213.00K | 278.00K | -544.00K | -298.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.70M | -10.21M | -7.63M | 1.64M | 8.33M |